ReviewSeminars in nuclear medicine2025
Mucin-Targeted Antibodies for Ovarian Cancer.
Review in Seminars in nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Ovarian cancer remains a leading cause of gynecologic cancer mortality, driven in part by late-stage diagnoses and high recurrence rates. Among emerging molecular targets, mucins-highly glycosylated transmembrane glycoproteins overexpressed and aberrantly glycosylated in epithelial ovarian cancers-have garnered increasing interest for both imaging and therapeutic strategies. This review highlights the expression profiles and clinical implications of key mucins (MUC1, MUC16) and evaluates antibody-based modalities that leverage these targets for enhanced tumor detection and treatment. We discuss the current landscape of therapeutic strategies, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and radioimmunotherapy, with emphasis on recent preclinical and clinical advances. We also examine the role of mucin-targeted antibodies in imaging and the integration of theranostic platforms. Key challenges such as antigen heterogeneity, immunogenicity, and tumor penetration are addressed, along with future directions for optimizing mucin-directed therapies. Together, these efforts underscore the ever-expanding potential of mucin-targeted immunotherapy to improve outcomes for patients with ovarian cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.